As shares of Cel-Sci Corp. (NYSEMKT:CVM) have traded to the upside of late, the company is set to gain more exposure when it presents at the "7th Annual Vaccines: All Things Considered Conference" in Washington, DC on Tuesday afternoon.
While I don't expect the Cel-Sci stock to lose any of the recent trading volatility - mostly due to what I consider to be obvious manipulation and a fair number of short shares that need to be covered (as of October) - I do believe that recent developments, including the Cel Sci-Johns Hopkins LEAPS H1N1 study, have re-enforced the long term positive outlook of the company.
Tuesday's presentation will not likely bring any new developments to the table, but there is enough pending news with Cel-Sci right now to keep both long- and short-term investors interested. Aside from the LEAPS H1N1 trial, news regarding the validation of the Baltimore area manufacturing facility continues to be expected in the fourth quarter.
Once that news is released, I then expect a news release announcing the commencement of the long awaited Multikine Phase III trial to follow shortly thereafter.
With volatility of the CVM stock likely to continue, I maintain my position of buying the dips. I think that we have a winner with CVM - especially for those with a long term outlook.
Disclosure: VFC is long CVM.